Corvus Pharmaceuticals (NASDAQ:CRVS) Given "Overweight" Rati

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $4.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 148.45% from the company’s previous close. […]

Related Keywords

, Virtu Financial , Cantor Fitzgerald , Nasdaq , Corvus Pharmaceuticals Company Profile , Corvus Pharmaceuticals Trading Down , Institutional Trading Of Corvus Pharmaceuticals , Renaissance Technologies , News Ratings For Corvus Pharmaceuticals Daily , Corvus Pharmaceuticals , Corvus Pharmaceuticals Inc , Charles Schwab Investment Management Inc , Tower Research Capital , Get Free Report , Pharmaceuticals Trading Down , Research Capital , Street Corp , Charles Schwab Investment Management , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Ccrvs , Medical , Reiterated Rating ,